CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis

Kuang, Lei; Song, Weimin; Qing, Hong-Yuan; Yan, Shi; Song, Fengju

doi:10.4238/2015.april.27.6

Cited by 23 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are many research investigated the urine cyfra21-1 is a useful tumor marker for bladder cancer [11][12][13]. And there are many research investigated that cyfra21-1 level may be a diagnostic biomarker for diagnosing bladder cancer [14,15]. In a retrospective single center study including 85 patients examined Serum cyfra21-1 seems to be a marker of advanced and high-grade urothelial carcinoma of the bladder.…”

Section: Discussionmentioning

confidence: 99%

Serum cyfra21-1 associated with biological aggressiveness and poor prognosis in male patients with urothelial carcinoma of bladder.

Heng

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : To assess the prognostic value of preoperative serum cyfra21-1 in male patients with urothelial carcinoma of bladder treated with radical cystectomy.Methods: Patients underwent radical cystectomy from 2009-2018 at our center were retrospectively analyzed and 267 male patients met our criterions. The median follow-up was 34 months. The serum level of cyfra21-1 was measured using enzyme linked immunosorbent assay. Patients were divided into two groups (cyfra21-1≤3.30ng/ml and cyfra21-1>3.30 ng/ml). Clinical significance of cyfra21-1 level was assessed.Results: Of the 267 patients, 110 (41.2%) had normal cyfra21-1, while 157 (58.8%) had elevated serum cyfra21-1. The prevalence of lymph node involvement, locally advanced stage (≥ pT3), tumor stages, tumor size and papillary were significantly higher in patients with elevated cyfra21-1 than in those with normal cyfra21-1. Patients with high cyfra21-1 showed worse Disease free survival and Overall survival than those with low cyfra21-1 ( P = 0.001 and 0.007, respectively). In multivariate analysis, High cyfra21-1, lymph node involvement, lymphovascular invasion and papillary were independent predictors of worse Disease free survival ( P = 0.036, <0.001, 0.002, 0.014 respectively). High cyfra21-1, lymph node involvement and lymphovascular invasion were also confirmed as independent predictors of worse Overall survival ( P = 0.038, 0.010, 0.005, respectively.)Conclusions: Elevated cyfra21-1 was associated with greater biological aggressiveness and worse prognosis than normal cyfra21-1.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum cyfra21-1 associated with biological aggressiveness and poor prognosis in male patients with urothelial carcinoma of bladder.

Heng

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…20-24 CYFRA 21-1 was shown to be elevated in 46% (six of 13) of all cases of EMPD, including 100% (five of five) of metastatic samples. 25 While these data strongly suggest that serum CEA and CYFRA 21-1 levels will be prospective candidates for tumour biomarkers of EMPD, [17][18][19][20][21][22][23][24][25] the accuracy of these potential associations has not been fully characterized. Furthermore, the correlation between these biomarkers has not been reported in patients with EMPD.…”

Section: Discussionmentioning

confidence: 99%

“…CK19 is a low‐molecular‐weight (40 kDa) acidic type I keratin that is widely expressed in epithelial cells, forming an integral part of the of epithelial cytoskeleton . Elevated serum CYFRA 21‐1 levels have been reported in several malignancies, including non‐small cell lung cancer, breast cancer, gastric cancer, nasopharyngeal carcinoma and bladder cancer . CYFRA 21‐1 was shown to be elevated in 46% (six of 13) of all cases of EMPD, including 100% (five of five) of metastatic samples …”

mentioning

confidence: 96%

See 1 more Smart Citation

Serum cytokeratin 19 fragment 21‐1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease

et al. 2019

View full text Add to dashboard Cite

Summary Background Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma affecting the genitals and axillary regions. As metastasis of these tumours is itself rare, solid disease management strategies have not been established. Serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21‐1 (CYFRA 21‐1) levels have been identified as candidate biomarkers for tumour progression in EMPD. Objectives To determine the accuracy of and the correlation between these markers in patients with EMPD. Methods Serum CEA and CYFRA 21‐1 levels were examined in 30 patients with EMPD treated at Keio University Hospital, and compared against clinical information. Both assays were performed at the time of diagnosis, during the postoperative observation period, and following systemic treatment in those with confirmed metastasis. Serum levels were then correlated with tumour progression status and treatment responses. Results Normal levels for both assays were observed in all 11 patients with primary localized disease (100%). In patients with metastatic disease the CEA positivity rate was 79% (15 of 19 patients), with a rate of 63% (12 of 19 patients) for CYFRA 21‐1. Changes in CEA and CYFRA 21‐1 levels were statistically independent; however, using a combined view, elevated levels of either marker improved the positivity rate to 95% (18 of 19 patients). Use of both markers also correlated well with treatment responses. Conclusions The combination of CEA and CYFRA 21‐1 is useful for predicting metastasis and treatment response in patients with EMPD, especially in those who only have elevation of a single marker. What's already known about this topic? Serum levels of carcinoembryonic antigen (CEA) and cytokine 19 fragment 21‐1 (CYFRA 21‐1) have been shown to be elevated in patients with extramammary Paget disease (EMPD). Elevation of serum CEA levels is associated with tumour progression of EMPD. A single small study reported that serum CYFRA 21‐1 levels are elevated in patients with EMPD with lymph node metastasis. What does this study add? Serum CEA and CYFRA 21‐1 were present in 79% and 63% of 19 cases of metastatic EMPD, respectively. Elevations of CEA and CYFRA 21‐1 were statistically independent. CEA and CYFRA 21‐1 combination assays were positive in 95% of cases of metastatic EMPD. What is the translational message? Combination assays with CEA and CYFRA 21‐1 are useful for monitoring treatment response in patients with metastatic EMPD, particularly in those with elevation of either marker.

show abstract

“…There is evidence for the expression of both of these proteins in oral cavity and whole blood (Gene Cards, GCID:GC17M041460 and GCID:GC12M052377). Expression profiles of keratins in blood have been suggested to serve as potential biomarkers for different cancers such as OSCC, bladder cancer and small cell lung cancer ( Lee et al , 2012 ; Hsu et al , 2015 ; Kuang et al , 2015 ). Among the upregulated protein in OSCC serum is another S-Plot significant protein, which can classify the OSCC and healthy serum, named as ribonuclease pancreatic (RNASE1).…”

Section: Discussionmentioning

confidence: 99%

Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics

Saraswat¹,

Mäkitie²,

Agarwal³

et al. 2017

Br J Cancer

View full text Add to dashboard Cite

Background:No blood biomarkers to detect early oral cavity squamous cell carcinoma (OSCC) without clinical signs exist – diagnosis is solely based on histology of a visible tumour. Most OSCC patients are diagnosed at advanced stage, which leads to significant morbidity and poor survival. Our aim was to find the serum screening or detection biomarkers in OSCC.Methods:Serum samples from patients with OSCC treated at the Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University Hospital (Finland) were collected. Age- and gender-matched healthy individuals served as controls. Quantitative label-free proteomics in high definition MSE mode(HDMSE) was performed on 13 patients and 12 healthy samples. Various statistical analyses were performed on quantitative proteomics data to obtain the most influential proteins, which classify the patients vs healthy samples.Results:In quantitative proteomic analysis (HDMSE), 388 proteins were quantified in our pilot study. A complete separation between cases and controls was seen in supervised and unsupervised classification techniques such as orthogonal projections on latent structure-discriminant analysis (OPLS-DA) and self-organising maps. Using OPLS-DA S-plot, we identified a set of eight proteins that completely separated OSCC patients from healthy individuals.Conclusions:Although the tumour stages varied from I to IVa, these potential biomarkers were able to identify all OSCCs demonstrating their sensitivity to detect tumours of all stages. We are the first to suggest a set of serum biomarkers in our pilot study to be evaluated further as a diagnostic panel to detect preclinical OSCC in risk patients.

show abstract

CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis

Cited by 23 publications

References 22 publications

Serum cyfra21-1 associated with biological aggressiveness and poor prognosis in male patients with urothelial carcinoma of bladder.

Serum cyfra21-1 associated with biological aggressiveness and poor prognosis in male patients with urothelial carcinoma of bladder.

Serum cytokeratin 19 fragment 21‐1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease

Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics

Contact Info

Product

Resources

About